Table 3.

Hematologic, chemical, and iron indices and rate of responders in treatment groupsa

ParameterControlb (n = 65)Intravenous Ironb (n = 64)Pc
BaselineFinalCFBBaselineFinalCFB
Hemoglobin (g/dl)10.2 ± 0.711.3 ± 1.41.1 ± 1.4f10.4 ± 0.811.9 ± 1.31.6 ± 1.3f0.028
Respondersd (%)29.246.90.041
CHre (pg)31.0 ± 2.830.2 ± 2.8−0.9 ± 1.6f31.4 ± 2.731.4 ± 2.50.0 ± 2.20.011
Serum ferritin (ng/ml)765 ± 193591 ± 274−174 ± 225f759 ± 190929 ± 297173 ± 272f<0.001
TSAT (%)19.0 ± 4.121.1 ± 5.81.8 ± 5.2f18.2 ± 4.225.6 ± 7.67.5 ± 7.4f<0.001
  • a CFB, change from baseline.

  • b Control group received no iron treatment; intravenous iron group received 1 g of ferric gluconate (125 mg during eight consecutive dialysis treatments).

  • c P value comparing between-group difference in CFB (hemoglobin, CHr, serum ferritin, and TSAT) and in proportion of responders in the two groups.

  • d Responders all were patients who experienced a CFB in hemoglobin ≥2 g/dl at any point in the study.

  • e CHr was obtained using the Advia 120 analyzer (Bayer Diagnostics, Tarrytown, NY).

  • f Within-group CFB is statistically significant (P < 0.05).